Clinical Trial Update: Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating a combination of bexarotene and rosiglitazone for cutaneous T-cell lymphoma has been completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Rosiglitazone (rosiglitazone)
• Targretin (bexarotene)

Snippet

Sponsor: Vanderbilt University | Conditions: Cutaneous T-cell Lymphoma, Mycosis Fungoides | Phase 2 | Status: COMPLETED | Results posted: 2016-02-17